1. La doxycycline ou comment faire du neuf avec du vieux ?
- Author
-
Nathalie Shehwaro, Marion Gauthier, Anne-Lyse Langlois, Maud Casenave, Victor Gueutin, and Hassane Izzedine
- Subjects
Periodontitis ,Doxycycline ,medicine.medical_specialty ,business.industry ,Angiogenesis ,Proteolytic enzymes ,Inflammation ,Matrix metalloproteinase ,medicine.disease ,Surgery ,Rosacea ,Rheumatoid arthritis ,medicine ,Cancer research ,Pharmacology (medical) ,medicine.symptom ,skin and connective tissue diseases ,business ,medicine.drug - Abstract
Tetracyclines are broad-spectrum antibiotics that interfere with protein synthesis. They were first widely prescribed by dermatologists in the early 1950s in the treatment of acne. More recently, their biological actions on inflammation, proteolysis, angiogenesis, apoptosis, metal chelation, ionophoresis, and bone metabolism were studied. Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that degrade components of the extracellular matrix (ECM). MMPs have direct or indirect effects on the vascular endothelium and the vascular relaxation/contraction system. The therapeutic effects of tetracyclines and analogues were studied in rosacea, bullous dermatoses, neutrophilic diseases, pyoderma gangrenosum, sarcoidosis, aortic aneurysms, cancer metastasis, periodontitis and autoimmune diseases autoimmune diseases such as rheumatoid arthritis and scleroderma. In addition, downregulation of MMP using doxycycline could be beneficial in reducing vascular dysfunction mediated by MMPs and progressive damage of the vascular wall. We review the nonantibiotic properties of doxycycline and its potential clinical applications.
- Published
- 2014